302 related articles for article (PubMed ID: 30526254)
1. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.
Lu X; Nobrega RP; Lynaugh H; Jain T; Barlow K; Boland T; Sivasubramanian A; Vásquez M; Xu Y
MAbs; 2019 Jan; 11(1):45-57. PubMed ID: 30526254
[TBL] [Abstract][Full Text] [Related]
2. Quantification of in vivo site-specific Asp isomerization and Asn deamidation of mAbs in animal serum using IP-LC-MS.
Mehl JT; Sleczka BG; Ciccimaro EF; Kozhich AT; Gilbertson DG; Vuppugalla R; Huang CS; Stevens B; Mo J; Deyanova EG; Wang Y; Huang RY; Chen G; Olah TV
Bioanalysis; 2016 Aug; 8(15):1611-1622. PubMed ID: 27397670
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures.
Diepold K; Bomans K; Wiedmann M; Zimmermann B; Petzold A; Schlothauer T; Mueller R; Moritz B; Stracke JO; Mølhøj M; Reusch D; Bulau P
PLoS One; 2012; 7(1):e30295. PubMed ID: 22272329
[TBL] [Abstract][Full Text] [Related]
4. Qualification of a Quantitative Method for Monitoring Aspartate Isomerization of a Monoclonal Antibody by Focused Peptide Mapping.
Cao M; Mo WD; Shannon A; Wei Z; Washabaugh M; Cash P
PDA J Pharm Sci Technol; 2016 11/12; 70(6):490-507. PubMed ID: 27091886
[TBL] [Abstract][Full Text] [Related]
5. Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based
Hoffmann D; Bauer J; Kossner M; Henry A; Karow-Zwick AR; Licari G
MAbs; 2024; 16(1):2333436. PubMed ID: 38546837
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening of antibody variants for chemical stability: identification of deamidation-resistant mutants.
DiCara DM; Andersen N; Chan R; Ernst JA; Ayalon G; Lazar GA; Agard NJ; Hilderbrand A; Hötzel I
MAbs; 2018 Oct; 10(7):1073-1083. PubMed ID: 30130444
[TBL] [Abstract][Full Text] [Related]
7. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies.
Wakankar AA; Borchardt RT; Eigenbrot C; Shia S; Wang YJ; Shire SJ; Liu JL
Biochemistry; 2007 Feb; 46(6):1534-44. PubMed ID: 17279618
[TBL] [Abstract][Full Text] [Related]
8. Structure-Function Assessment and High-Throughput Quantification of Site-Specific Aspartate Isomerization in Monoclonal Antibody Using a Novel Analytical Tool Kit.
Zhou K; Cao X; Bautista J; Chen Z; Hershey N; Ludwig R; Tao L; Zeng M; Das TK
J Pharm Sci; 2020 Jan; 109(1):422-428. PubMed ID: 31469998
[TBL] [Abstract][Full Text] [Related]
9. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.
Azevedo Reis Teixeira A; Erasmus MF; D'Angelo S; Naranjo L; Ferrara F; Leal-Lopes C; Durrant O; Galmiche C; Morelli A; Scott-Tucker A; Bradbury ARM
MAbs; 2021; 13(1):1980942. PubMed ID: 34850665
[TBL] [Abstract][Full Text] [Related]
10. Engineering an anti-CD52 antibody for enhanced deamidation stability.
Qiu H; Wei R; Jaworski J; Boudanova E; Hughes H; VanPatten S; Lund A; Day J; Zhou Y; McSherry T; Pan CQ; Sendak R
MAbs; 2019 Oct; 11(7):1266-1275. PubMed ID: 31199181
[TBL] [Abstract][Full Text] [Related]
11. N+1 Engineering of an Aspartate Isomerization Hotspot in the Complementarity-Determining Region of a Monoclonal Antibody.
Patel CN; Bauer SP; Davies J; Durbin JD; Shiyanova TL; Zhang K; Tang JX
J Pharm Sci; 2016 Feb; 105(2):512-518. PubMed ID: 26869414
[TBL] [Abstract][Full Text] [Related]
12. Biophysical and Sequence-Based Methods for Identifying Monovalent and Bivalent Antibodies with High Colloidal Stability.
Alam ME; Geng SB; Bender C; Ludwig SD; Linden L; Hoet R; Tessier PM
Mol Pharm; 2018 Jan; 15(1):150-163. PubMed ID: 29154550
[TBL] [Abstract][Full Text] [Related]
13. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
14. A High-Throughput Bioluminescent Assay to Monitor the Deamidation of Asparagine and Isomerization of Aspartate Residues in Therapeutic Proteins and Antibodies.
Hsiao K; Alves J; Patel R; Adams M; Nashine V; Goueli S
J Pharm Sci; 2017 Jun; 106(6):1528-1537. PubMed ID: 28263844
[TBL] [Abstract][Full Text] [Related]
15. An Automated and Qualified Platform Method for Site-Specific Succinimide and Deamidation Quantitation Using Low-pH Peptide Mapping.
Cao M; Xu W; Niu B; Kabundi I; Luo H; Prophet M; Chen W; Liu D; Saveliev SV; Urh M; Wang J
J Pharm Sci; 2019 Nov; 108(11):3540-3549. PubMed ID: 31374319
[TBL] [Abstract][Full Text] [Related]
16. Developability assessment during the selection of novel therapeutic antibodies.
Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody.
Sreedhara A; Cordoba A; Zhu Q; Kwong J; Liu J
Pharm Res; 2012 Jan; 29(1):187-97. PubMed ID: 21809161
[TBL] [Abstract][Full Text] [Related]
18. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
[TBL] [Abstract][Full Text] [Related]
19. Identification of deamidation and isomerization sites on pharmaceutical recombinant antibody using H(2)(18)O.
Terashima I; Koga A; Nagai H
Anal Biochem; 2007 Sep; 368(1):49-60. PubMed ID: 17617368
[TBL] [Abstract][Full Text] [Related]
20. Biophysical properties of the clinical-stage antibody landscape.
Jain T; Sun T; Durand S; Hall A; Houston NR; Nett JH; Sharkey B; Bobrowicz B; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Baruah H; Gray LT; Krauland EM; Xu Y; Vásquez M; Wittrup KD
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):944-949. PubMed ID: 28096333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
